Peer-influenced content. Sources you trust. No registration required. This is HCN.
ASH Clinical News
The investigational new drug (IND) application is for GDX012, which also received an FDA orphan drug designation for the treatment of acute myeloid leukemia (AML). The drug’s manufacturer, GammaDelta Therapeutics, is developing the T-cell platform in partnership with Takeda and will initiate a phase I study in late 2021 that will evaluate the treatment’s safety and activity in patients with measurable residual disease-positive AML.
Hematology June 21st 2021
Journal of Clinical Oncology
An update from the original ASCO guideline on this topic published in 2012, 60 studies, primarily retrospective, were included in the review. New to this version of the guideline, the Panel offers recommendations on approved doses of immunotherapy and targeted therapies that can be offered to obese patients with cancer.
Endocrinology, Diabetes, Metabolism June 21st 2021
JAMA Network
In this JAMA Original Investigation, the researchers studied 19,529 patients with Medicare coverage who initiated first systemic therapy for advanced non–small cell lung cancer (NSCLC) using 1 of 4 regimens of checkpoint inhibitor immunotherapy, cytotoxic chemotherapy, and combined chemoimmunotherapy. The goal? To gauge the uptake and effectiveness of immunotherapy among older patients outside clinical trials.
Geriatrics June 2nd 2021
According to new research from the University of East Anglia (UEA) and published in the journal Proceedings of the Royal Society B, food intake has a detrimental effect on three generations of offspring—particularly when those descendants have access to unlimited food. They learned this through the study of food intake in 2,500 roundworms (Caenorhabditis elegans) split across four generations.
Endocrinology, Diabetes, Metabolism May 19th 2021
In this Original Report from the Journal of Clinical Oncology, the authors hypothesized that hematopoietic cell transplantation (HCT) with a mismatched unrelated donor (MMUD) using post-transplant cyclophosphamide (PTCy), a novel strategy successful in overcoming genetic disparity using mismatched related donors, would be feasible and increase access to HCT. Was their hypothesis correct?
Hematology May 5th 2021
The American Journal of Clinical Nutrition recently published a report that suggested reverse causality – disease driving behavior – may account for some of the controversies surrounding studies related to coffee consumption. The results showed those who have higher blood pressure drink less coffee and those with low blood pressure drank more. But what role does genetics play?
Cardiology April 27th 2021